Newsroom
Company updates and notices
Announcements from Ergopharm — company updates, quality and serialisation notices, and product register changes.
Product register expanded to twelve monographs
The export portfolio now spans injectables, oral solids and post-cycle therapy, each with a serialised monograph.
GS1 DataMatrix applied across all cartons
Every pack now leaves the line with a unique serial and human-readable data line, verifiable online.
Post-cycle therapy range added to the register
Tamoxifen and clomiphene monographs join the oral-solid portfolio.
Second oral-solid packaging line commissioned
Additional blister and bulk capacity added to meet export demand.
Online pack verification portal launched
Distributors and patients can confirm a carton from the code printed on its serialisation panel.
Serialisation and aggregation line commissioned
GS1 DataMatrix printing, in-line vision verification and case aggregation added at the end of the line.
Boldenone and trenbolone monographs added
The injectable range expands to six esters.
Cold-chain export lanes qualified
Temperature-controlled lanes validated for international distribution under GDP.
Safety features live across the portfolio
A unique identifier and anti-tampering device are applied to every outer carton.
Oral-solid-dose facility opened
Granulation, compression and coating brought in-house.
First export distribution agreements signed
Ergopharm begins supplying licensed distributors across export markets.
Sterile fill–finish line qualified
Aseptic ampoule filling under Grade A / B commissioned and qualified.
Quality control laboratory established
In-house analytical testing introduced for identity, assay and stability.
Ergopharm Advanced Research Centre founded
The company is established in Vadodara, Gujarat, to manufacture prescription medicines for export.